Arosio M, Bazzoni N, Faglia G
Ospedale Maggiore IRCCS, Università di Milano, Istituto de Scienze Endocrine.
Minerva Endocrinol. 1990 Jan-Mar;15(1):29-36.
Octreotide, an analog of somatostatin, is a valid tool for the cure of acromegalic disease. This compound has a prolonged half-life and is more selective than native somatostatin in suppressing growth hormone (GH) secretion. Octreotide, 100 micrograms tid sc, decreases GH levels and improves clinical symptoms in about 85% of acromegalic patients, lowering GH to below 5 ng/ml in 45% and to below 2 ng/ml in 17-21%. Octreotide normalizes somatomedin-C (IGF-I) levels in 36-50% of patients. The increase of dosage up to 1500 micrograms/day does not appear useful in poor responsive patients. No adverse effects on other endocrine functions submitted to hypothalamus-pituitary control have been observed. A slight shrinkage of the pituitary tumor is observed in 30-50% of cases. Octreotide therapy is well tolerated and side effects are usually mild. However the possibility of colelithiasis, liver damage and diabetes mellitus in patients with glucose intolerance must be taken into account. In conclusion octreotide is a useful complement to therapeutic means now used for the treatment of acromegaly.
奥曲肽是一种生长抑素类似物，是治疗肢端肥大症的有效药物。这种化合物半衰期延长，在抑制生长激素（GH）分泌方面比天然生长抑素更具选择性。皮下注射奥曲肽，100微克，每日三次，可使约85%的肢端肥大症患者的GH水平降低并改善临床症状，45%的患者GH降至5纳克/毫升以下，17 - 21%的患者降至2纳克/毫升以下。奥曲肽可使36 - 50%的患者的胰岛素样生长因子-C（IGF-I）水平恢复正常。对于反应不佳的患者，增加剂量至每日1500微克似乎并无益处。未观察到对受下丘脑-垂体控制的其他内分泌功能有不良影响。30 - 50%的病例中观察到垂体瘤略有缩小。奥曲肽治疗耐受性良好，副作用通常较轻。然而，必须考虑到糖耐量异常患者发生胆石症、肝损伤和糖尿病的可能性。总之，奥曲肽是目前用于治疗肢端肥大症的治疗手段的有益补充。
